-
Binance says resuming withdrawals after major hack
-
Shnaider beats Fernandez to win Tokyo title
-
Divided Bulgaria votes in tense presidential runoff
-
Winds of change: Laos looks up for renewables push
-
Trump says US looking 'closely' at report Nvidia CEO target of China spy plot
-
Sri Lanka's war widows and the long search for the missing
-
Maxey scores 38 to lead Sixers 'fighters' to another comeback win
-
'Air-con nation' Singapore eyes alternatives to cool down
-
Valkyries defeat Dream to capture first WNBA crown
-
US judge dismisses Trump lawsuit against Wall Street Journal over Epstein letter
-
'Seen and heard': Uruguay neighborhood places hopes in pope
-
Slave or not? US gallery shows early photos of African Americans
-
Spewing US election falsehoods, AI chatbots face scrutiny
-
France's Aymoz wins Skate Canada men's crown
-
EU's new levy on parcels kicks in
-
Pope Leo readies for 'intense' South America homecoming
-
Ocon denies reports of altercation after being dumped by Haas
-
Antonelli admits to feeling tense of eve of potential F1 title decider
-
Hamilton says love of racing keeps him young
-
FBI says North Korea behind $6 billion crypto theft from Binance
-
'Disgraceful' Australia face reckoning after South Africa humbling
-
'Canelo' Alvarez wins back WBC title from Mbilli in Riyadh
-
Sovereignty wins Breeders' Cup Classic, Benvenuto Cellini triumphs in Turf for O'Brien
-
'Canelo' Alvarez wins back WBC title from Mbilli
-
Hamilton takes record 105th pole and first for Ferrari, as Antonelli lurks
-
Sovereignty wins Breeders' Cup Classic
-
German rioters loot shops as 'Gen Z' demos turn ugly
-
Hamilton grabs pole position for Mexican Grand Prix
-
Barca hammer Alaves to retain Liga top spot
-
Benvenuto Cellini wins Breeders' Cup Turf
-
UK king to address Commonwealth with 'unflinching honesty' amid slavery focus
-
Roma thrash Udinese ahead of Milan derby
-
US judge dismisses Trump lawsuit against Wall Steet Journal over Epstein letter
-
Kane laments Dortmund draw after 'incredible high' of Ballon d'Or
-
Polish president holds crisis talks in court standoff
-
Spanish village holds memorial mass for train crash victims
-
NFL to review new allegations against Packers' Jacobs: reports
-
Israeli protesters demand opposition ally with Arab parties to oust Netanyahu
-
Le Havre owners sack coach after PSG thrashing
-
De Minaur upsets Zverev and will face Alcaraz in Vienna final
-
De Minaur upsets Zverev and will face Alacaraz in Vienna final
-
Kane misses penalty as Bayern held by Dortmund
-
German police, protesters clash after 'Gen Z' demos
-
In Mexico City, Day of the Dead parade inspired by 007
-
Fresh frustration for Maresca as Man City lose to Brighton
-
Rubio flags challenges in finding consensus as G20 talks wrap
-
Norris fastest ahead of Antonelli in final Mexico practice
-
Zaman's century foils Sri Lanka as Pakistan win tri-series
-
Hammers boss Nuno under pressure after West Brom loss
-
Bordeaux edge Bayonne to keep pressure on Toulouse
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
P.M.Smith--AMWN